CAR T cells have shown extraordinarily high activity against CD19+ hematological malignancies [2,3], and great efforts are undertaken to develop CAR T cells for the treatment of other hematological malignancies and solid tumors. The gene discussed is CD19; the disease is hematologic disorder.